4.7 Article

A Pretreatment Prognostic Score to Stratify Survival in Pancreatic Cancer

期刊

ANNALS OF SURGERY
卷 276, 期 6, 页码 E914-E922

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/SLA.0000000000004845

关键词

CA19-9; neoadjuvant therapy; pancreatic cancer; pretreatment score; prognosis; survival

类别

向作者/读者索取更多资源

This study developed and validated a prognostic score for pancreatic cancer based on pretreatment parameters. The score, called HELPP-score, was able to stratify survival independently of resection status and pathological tumor stage.
Objective:The aim of this study was to develop and validate a pretreatment prognostic score in pancreatic cancer (PDAC). Background:Pretreatment prognostication in PDAC is important for treatment decisions but remains challenging. Available prognostic tools are derived from selected cohorts of patients who underwent resection, excluding up to 20% of patients with exploration only, and do not adequately reflect the pretreatment scenario. Methods:Patients undergoing surgery for PDAC in Heidelberg from July 2006 to June 2014 were identified from a prospective database. Pretreatment parameters were extracted from the database and the laboratory information system. Parameters independently associated with overall survival by uni- and multivariable analyses were used to build a prognostic score. A contemporary cohort from Verona was used for external validation. Results:In 1197 patients, multiple pretreatment parameters were associated with overall survival by univariable analyses. American Society of Anesthesiology classification, carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen, C-reactive protein, albumin, and platelet count were independently associated with survival and were used to create the Heidelberg Prognostic Pancreatic Cancer (HELPP)-score. The HELPP-score was closely associated with overall survival (median survival between 31.3 and 4.8 months; 5-year survival rates between 35% and 0%) and was able to stratify survival in subgroups with or without resection as well as in CA19-9 nonsecretors. In the resected subgroup the HELPP-score stratified survival independently of pathological prognostic factors. The HELPP-score was externally validated and was superior to CA19-9 in both the development and validation cohorts. Conclusion:The HELPP-score is a readily available prognostic tool based on pretreatment routine parameters to stratify survival in PDAC independently of resection status and pathological tumor stage.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据